T1	p 246 284	patients with asthma poorly controlled
T2	p 288 291	low
T3	p 691 782	adult asthmatics . METHODS Sixty-six subjects were randomised to SFC or FP/M for 12 weeks .
T4	i 6 91	Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast
T5	i 305 320	corticosteroids
T6	i 433 451	placebo-controlled
T7	i 504 566	salmeterol plus fluticasone propionate ( FP ) ( Seretide ; SFC
T8	i 573 599	FP plus montelukast ( FP/M
T9	i 763 767	FP/M
T10	o 153 172	airway inflammation
T11	o 395 409	inflammation .
T12	o 602 687	on sputum inflammatory markers , airway responsiveness , lung function , and symptoms
T13	o 815 927	in neutrophil , eosinophil , macrophage , lymphocyte , and epithelial cell levels in induced sputum . Additional
T14	o 950 1067	change in other sputum markers of airway inflammation , airway responsiveness , symptom control , and lung function .
T15	o 1121 1156	induced sputum inflammatory cells ,
T16	o 1190 1223	reduction in sputum eosinophils .
T17	o 1263 1284	airway responsiveness
T18	o 1340 1373	symptom control and lung function
T19	o 1420 1463	reductions in sputum cysteinyl leukotrienes
T20	o 1575 1607	eosinophilic airway inflammation
T21	o 1619 1622	PEF
T22	o 1627 1634	symptom